From Independent Innovation to Global Expansion: Changping Builds a World-Class High-End Medical Device Industry Hub

Beijing, June 30 (China Economic Network) — Reporter Guo Wenpei: With the 2026 Beijing-Changping Life Science Forum and the 43rd National Pharmaceutical Industry Information Annual Conference set to commence on June 26, journalists from central, municipal, and industry media visited the Changping Medical Device Industry Cluster. They conducted field visits to key parks and enterprises, including Changfazhan International Medical Device City, New Cloud Medical, Weigao Smart Healthcare, and Beijing Dayi, to investigate the latest achievements of the local high-end medical device industry in breakthroughs in core technologies, product research and development iteration, clinical application, and commercialization layout. As a core component of Beijing’s International Science and Technology Innovation Center, Changping relies on two key platforms—Zhongguancun Life Science Park and the International Medical Device City—to continuously strengthen its position as a globally competitive hub for the high-end medical device industry.

New Cloud Medical, a specialized and innovative enterprise deeply rooted in the field of novel medical devices for chronic pain, has established three core pipelines—brain-computer interfaces (BCI), neuromodulation, and minimally invasive interventional therapies—creating a tiered product system tailored to the full-cycle diagnosis and treatment of pain. According to company leadership, its product portfolio features a three-tier strategic layout: At the base level, the NewMild® minimally invasive interventional products specifically address lumbar spinal stenosis caused by ligamentum flavum hypertrophy. At the middle level, the NewStim® AI-closed-loop spinal cord stimulation system provides solutions for intractable pain refractory to pharmacological treatment, representing a mature, commercially implemented invasive brain-computer interface product. At the pinnacle, the C-7® implantable pain brain-computer interface system focuses on intractable pain unresponsive to conventional therapies. This system directly acquires raw electroencephalographic (EEG) signals from the brain's pain centers, establishing an advanced bidirectional closed loop. By leveraging AI algorithms, it transforms patients' subjective pain sensations into quantifiable and monitorable objective neural data, enabling precise targeted therapy that intervenes at the source for conditions such as central sensitization and multi-site complex intractable pain, where spinal cord stimulation often proves ineffective.

Weigao Smart, a subsidiary of Weigao Group focused on the R&D of orthopedic surgical robots, has secured its position in the industry through differentiated core technologies, with its flagship product, the Weiz-01 Total Knee Arthroplasty Navigation and Positioning System, demonstrating outstanding competitiveness. The company’s core barrier lies in its industry-exclusive “imaging + robot + implant” tripartite native synergy model, which achieves full-chain adaptation across imaging diagnosis, intelligent equipment, and native implant design. Leveraging an exclusive partnership with CurveBeam AI, its subsidiary Weiyi masters weight-bearing true biomechanical imaging data sources, addressing the industry pain point of distorted preoperative assessments. In clinical applications, the Weiz-01 has completed over 300 surgeries in more than 10 hospitals across China, achieving an excellent surgery rate of over 99%, sub-millimeter precision in bone cutting, and a 100% mechanical alignment compliance rate, leading the industry in clinical precision and stability.

As a benchmark enterprise for high-end domestically produced radiotherapy equipment, OUR UNITED CORPORATION is the leader in China’s Gamma Knife industry, with its products consistently ranking first in domestic market share. The company independently developed the world-exclusive X/γ ray integrated radiotherapy system (TaiChiRT), which is the only product among large-scale domestic radiotherapy devices to receive the U.S. FDA Breakthrough Device designation, demonstrating that its technological prowess has gained recognition from international authorities.

According to the company, conventional radiotherapy delivers non-discriminatory radiation doses to tumor tissues, which can easily damage surrounding healthy tissues. In contrast, the TaiChiRT system innovatively integrates the dual advantages of high-precision gamma-ray focusing and wide-area X-ray coverage. It differentially modulates radiation doses based on the biological characteristics of tumors, customizing precise treatment plans for different tumor regions. This approach enhances tumor eradication while maximizing the protection of healthy tissues, significantly improving both the safety and efficacy of treatment. Furthermore, the system enables Gamma Knife, linear accelerator, and combined-mode therapies within a single treatment room, allowing for the selection of the optimal regimen tailored to each patient’s condition. Currently, this domestically developed, original radiotherapy technology has successfully entered the North American market, with two units installed and in clinical use, facilitating the global expansion of China’s high-end medical equipment.

Leveraging high-quality infrastructure and industrial resources, the Changping Medical Device Industrial Park has established a comprehensive, full-chain industrial ecosystem, forming three core competitive advantages. First, deep integration of industry, academia, research, and clinical practice: Located in close proximity to top-tier (Grade 3A) hospitals such as Beijing Tsinghua Changgung Hospital and Jishuitan Hospital, the park collaborates with medical engineering and research departments at prestigious universities including Tsinghua University, Beihang University, and Beijing University of Chemical Technology. It regularly facilitates partnerships between enterprises, universities, and hospitals, creating a virtuous innovation loop characterized by “clinical needs defining problems, scientific research providing solutions, and enterprises developing products.” Second, comprehensive empowerment through professional platforms: The park has established public service platforms, including a Medical Device Innovation Service Station and Contract Development and Manufacturing Organizations (CDMOs), effectively reducing costs associated with R&D trial-and-error and pilot production, thereby accelerating product industrialization. Third, precise policy support across the entire lifecycle: By leveraging the pioneering policies of the Zhongguancun Demonstration Zone, the Changping Cluster of the Free Trade Zone, and special local industrial cluster policies, the park provides support covering all stages from R&D innovation, commercial production, and market promotion to overseas expansion. This forms a closed-loop industrial cultivation system, creating a “Changping Model” for the high-quality development of the medical device industry.